Abstract
Glioblastoma is a primary tumor of the brain with a poor prognosis. Pathological examination shows that this disease is characterized by intra-tumor morphological heterogeneity, while numerous and ongoing genomic analysis reveals multiple layers of heterogeneity. Intra-tumor and patient-to-patient heterogeneity is underpinned by cellular, genetic, and molecular heterogeneity, which is thought to be key determinants of time to tumor recurrence and resistance to therapy. The key cell type believed to contribute to the establishment and ongoing evolution of tumor heterogeneity is a glioma stem cell (GSC) subpopulation. In this chapter, we review, highlight, and discuss controversies and clinical relevance of glioblastoma heterogeneity and its cellular basis. Characterization of how cancer stem cells (CSCs) behave is important in understanding how tumors are initiated and how they recur following initial treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Al-Hajj M et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988
Anido J et al (2010) TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18:655–668
Aruffo A et al (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303–1313
Athanassiou-Papaefthymiou M et al (2014) Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol 27:337–349
Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141–179
Bayin NS et al (2017) Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. Oncotarget 8:64932–64953
Baysan M et al (2014) Micro-environment causes reversible changes in DNA methylation and mRNA expression profiles in patient-derived glioma stem cells. PLoS ONE 9:e94045
Beier D et al (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010–4015
Bhat KPL et al (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24:331–346
Bittner M et al (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536–540
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737
Branda CS, Dymecki SM (2004) Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6:7–28
Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Investig 84:397–405
Brennan CW et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477
Brown DV et al (2017) Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PLoS One 12:e0172791
Burney MJ et al (2013) An epigenetic signature of developmental potential in neural stem cells and early neurons. Stem Cells 31:1868–1880
Capela A, Temple S (2002) LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal. Neuron 35:865–875
Caramel J et al (2013) A switch in the expression of embryonic EMT-inducers drivesthe development of malignant melanoma. Cancer Cell 24:466–480
Chaffer CL et al (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. PNAS 108:7950–7955
Chaffer CL et al (2013) Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154:61–74
Chambers I et al (2007) Nanog safeguards pluripotency and mediates germline development. Nature 450:1230–1234
Chen R et al (2010) A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17:362–375
Choi SA et al (2014) Identification of brain tumour initiating cells using the stem cell marker aldehyde dehydrogenase. Eur J Cancer 50:137–149
Chow LML et al (2011) Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19:305–316
Chung AS et al (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10:505–514
Clark SJ et al (2016) Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity. Genome Biol 17:72
Daniel PM et al (2018) Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures. Exp Mol Pathol 105:23–31
Deppe U et al (1978) Cell lineages of the embryo of the nematode Caenorhabditis elegans. Proc Natl Acad Sci U S A 75:376–380
Donnenberg VS, Donnenberg AD (2015) Stem cell state and the epithelial-to-mesenchymal transition: implications for cancer therapy. J Clin Pharmacol 55:603–619
Doucette T et al (2013) Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res 1:112–122
Farago AF et al (2006) Assembly of the brainstem cochlear nuclear complex is revealed by intersectional and subtractive genetic fate maps. Neuron 50:205–218
Frieda KL et al (2017) Synthetic recording and in situ readout of lineage information in single cells. Nature 541:107–111
Friedmann-Morvinski D et al (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338:1080–1084
Galli R et al (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021
Gerlinger M et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892
Grivennikov SI et al (2010) Immunity, inflammation, and cancer. Cell 140:883–899
Günthert U et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13–24
Gupta PB et al (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146:633–644
Habib N et al (2016) Div-Seq: single-nucleus RNA-Seq reveals dynamics of rare adult newborn neurons. Science 353:925–928
Haghverdi L et al (2016) Diffusion pseudotime robustly reconstructs lineage branching. Nat Methods 13:845–848
Halliday J et al (2014) In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. PNAS 111:5248–5253
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
Hayashi K et al (2008) Dynamic equilibrium and heterogeneity of mouse pluripotent stem cells with distinct functional and epigenetic states. Cell Stem Cell 3:391–401
Hoek KS et al (2008) In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 68:650–656
Holmberg Olausson K et al (2014) Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. PLoS ONE 9:e106694
Hu X-L et al (2012) Epigenetic control on cell fate choice in neural stem cells. Protein Cell 3:278–290
Ikawa M et al (1983) Isolation and characterization of aldehyde dehydrogenase isozymes from usual and atypical human livers. J Biol Chem 258:6282–6287
Jijiwa M et al (2011) CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 6:e24217
Jung CS et al (2011) Diagnostic markers for glioblastoma. Histol Histopathol 26:1327–1341
Kalhor R et al (2017) Rapidly evolving homing CRISPR barcodes. Nat Methods 14:195–200
Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401
Kelly PN et al (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317:337
Kern SE, Shibata D (2007) The fuzzy math of solid tumor stem cells: a perspective. Cancer Res 67:8985–8988
Kim K-J et al (2011) The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 31:494–502
Kim H et al (2015) Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25:316–327
Kirkpatrick JP et al (2017) Management of GBM: a problem of local recurrence. J Neuro-Oncol 134:487–493
Kolodziejczyk AA et al (2015) The technology and biology of single-cell RNA sequencing. Mol Cell 58:610–620
Lee JH et al (2018) Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560(7717):243–247
Lein E et al (2017) The promise of spatial transcriptomics for neuroscience in the era of molecular cell typing. Science 358:64–69
Li FZ et al (2015) Phenotype switching in melanoma: implications for progression and therapy. Front Oncol 5:31
Liu C et al (2011) Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146:209–221
Macaulay IC et al (2017) Single-cell multiomics: multiple measurements from single cells. Trends Genet 33:155–168
Magee JA et al (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:283–296
Mao P et al (2013) Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. PNAS 110:8644–8649
de Martel C et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615
Marusyk A et al (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334
Marzesco A-M et al (2005) Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 118:2849–2858
McGranahan N, Swanton C (2012) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 13:528–538
McKenna A et al (2016) Whole-organism lineage tracing by combinatorial and cumulative genome editing. Science 353:aaf7907
Meng J et al (2014) A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway. Oncotarget 5:4683–4693
Metellus P et al (2011) Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol 18:2937–2945
Meyer M et al (2015) Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. PNAS 112:851–856
Morrison SJ, Weissman IL (1994) The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1:661–673
Morrison SJ et al (1997) Identification of a lineage of multipotent hematopoietic progenitors. Development 124:1929–1939
Muller S et al (2017) Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol 18:234
Muramatsu T (1984) Cell surface glycoproteins as markers in monitoring in vitro differentiation of embryonal carcinoma cells. Cell Differ 15:101–108
Nathanson DA et al (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343:72–76
Navin NE (2015) The first five years of single-cell cancer genomics and beyond. Genome Res 25:1499–1507
Navin N et al (2011) Tumour evolution inferred by single-cell sequencing. Nature 472:90–94
Nguyen LV et al (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12:133–143
Papp B, Plath K (2013) Epigenetics of reprogramming to induced pluripotency. Cell 152:1324–1343
Patel AP et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396–1401
Pei W et al (2017) Polylox barcoding reveals haematopoietic stem cell fates realized in vivo. Nature 548:456–460
Persano L et al (2011) The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. Sci World J 11:1829–1841
Persano L et al (2012) BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1 alpha stability and MGMT expression. Cell Death Dis 3:e412
Phillips HS et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173
Pietras A et al (2014) Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14:357–369
Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437
Quintana E et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598
Rasper M et al (2010) Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro-Oncology 12:1024–1033
Rocco A et al (2012) CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. J Cell Physiol 227:2686–2693
Rong Y et al (2006) ‘Pseudopalisading’ necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65:529–539
Rooj AK et al (2017) MicroRNA-mediated dynamic bidirectional shift between the subclasses of glioblastoma stem-like cells. Cell Rep 19:2026–2032
Rothwell PM et al (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379:1591–1601
Ruiz P et al (1995) CD44 isoforms during differentiation and development. BioEssays 17:17–24
Schäfer A et al (2012) Aldehyde dehydrogenase 1A1-a new mediator of resistance to temozolomide in glioblastoma. Neuro-Oncology 14:1452–1464
Shackleton M et al (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138:822–829
Shmelkov SV et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120
Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
Singh SK et al (2004) Cancer stem cells in nervous system tumors. Oncogene 23:7267–7273
Sintupisut N et al (2013) An integrative characterization of recurrent molecular aberrations in glioblastoma genomes. Nucleic Acids Res 41:8803–8821
Snippert HJ et al (2010) Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143:134–144
Snuderl M et al (2011) Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810–817
Snyder A et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199
Son MJ et al (2009) SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4:440–452
Sottoriva A et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. PNAS 110:4009–4014
Stieber D et al (2014) Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol 127:203–219
Stricker SH et al (2013) Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev 27:654–669
Sugimori M et al (2015) Discovery of power-law growth in the self-renewal of heterogeneous glioma stem cell populations. PLoS One 10:e0135760
Svensson V et al (2018) Exponential scaling of single-cell RNA-seq in the past decade. Nat Protoc 13:599–604
Szerlip NJ et al (2012) Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. PNAS 109:3041–3046
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676
Teng J et al (2017) Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro-Oncology 19:820–832
Thorne RF et al (2004) The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci 117:373–380
Tirosh I et al (2016) Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature 539:309–313
Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4:528–539
Trapnell C et al (2014) The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol 32:381–386
Turner DL, Cepko CL (1987) A common progenitor for neurons and glia persists in rat retina late in development. Nature 328:131–136
Uchida N et al (2000) Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 97:14720–14725
Venet D et al (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7:e1002240
Verfaillie A et al (2015) Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun 6:6683
Verhaak RGW et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110
Vogt N et al (2004) Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci U S A 101:11368–11373
Waldner MJ, Neurath MF (2009) Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31:249–256
Wang J et al (2008) CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122:761–768
Weigmann A et al (1997) Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A 94:12425–12430
Welker AM et al (2017) Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma. Neuroscience 356:35–43
Yin AH et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012
Yu P et al (2010) Clinical significance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol 136:1283–1292
Zelová H, Hovsek J (2013) TNF-alpha signalling and inflammation: interactions between old acquaintances. Inflamm Res 62:641–651
Zhao LH et al (2015) CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Pathol 8:692–701
Zöller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11:254–267
Acknowledgements
TM is supported by grants from the Brain Foundation Australia and the CASS Foundation Australia.
Conflict of Interest
The authors have declared no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Brown, D.V., Stylli, S.S., Kaye, A.H., Mantamadiotis, T. (2019). Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance. In: Birbrair, A. (eds) Stem Cells Heterogeneity in Cancer. Advances in Experimental Medicine and Biology, vol 1139. Springer, Cham. https://doi.org/10.1007/978-3-030-14366-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-14366-4_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-14365-7
Online ISBN: 978-3-030-14366-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)